Tirzepatide clinical trials

Explore recruiting tirzepatide clinical trials.

Recruiting tirzepatide studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tirzepatide trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities

Germany, Belgium, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

I8F-MC-GPIX: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)

France, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

J1R-MC-GZFD: A Parallel-Group Treatment, Phase 2, Double-Blind study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants with Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide who Failed to Achieve HbA1c Goal

Germany, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

I6T-MC-AMCE: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohn’s Disease and Obesity or Overweight

Denmark, Hungary, Greece, Germany, Austria, Italy +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

I8F-MC-GPJA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants with Type 1 Diabetes and Obesity or Overweight

Denmark, France, Spain, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

I8F-MC-GPIG - Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)

Denmark, Austria, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Tirzepatide trials by city

Tirzepatide in Toronto Tirzepatide in Vancouver Tirzepatide in Montreal Tirzepatide in Calgary Tirzepatide in Edmonton Tirzepatide in Ottawa Tirzepatide in Winnipeg Tirzepatide in Quebec City Tirzepatide in Hamilton Tirzepatide in Kitchener Tirzepatide in London Tirzepatide in Halifax Tirzepatide in New York Tirzepatide in Los Angeles Tirzepatide in Chicago Tirzepatide in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease